Medpage Today on MSN5d
Adjuvant Nivolumab Boosts Survival Outcomes in Muscle-Invasive Bladder Cancer
Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of ...
Cancer Therapy Advisor4d
Benefits of Nivolumab-Cabozantinib Extend Beyond 5 Years in RCC
Nivolumab plus cabozantinib provides long-term benefits over sunitinib in advanced RCC, according to final results from CheckMate 9ER.
Cure Today4d
Adjuvant Opdivo Continues to Provide Survival Benefit in Patients With High-Risk MIUC
Among patients with muscle-invasive bladder cancer, adjuvant Opdivo showed a continued benefit in survival versus placebo.